Granting the wishes of anti-abortion groups, the Trump administration announced it will end fetal tissue research by government scientists; Insys Therapeutics has agreed to pay $225 million to settle federal investigations into allegations that the manufacturer paid kickbacks and used other illegal tactics to sell a powerful fentanyl spray; Medicaid enrollees who would potentially be subject to Medicaid work requirements are likely to face barriers to employment.
The Trump administration said Wednesday that they have discontinued all internal research that involves fetal tissue, putting an end to fetal tissue research by government scientists. The announcement was welcome news to anti-abortion activists, as fetal tissue is obtained through elective abortions. According to a statement from HHS, external fetal-tissue projects that receive government funding will continue, but new or renewed grant applications will require approval from an ethics advisory board. Scientists have spoken out against the announcement, saying that fetal tissue research has been essential to developing life-saving therapies.
Opioid manufacturer Insys Therapeutics has agreed to pay $225 million to settle federal investigations into allegations that the manufacturer paid kickbacks and used other illegal tactics to sell Susbys, a fentanyl spray meant for patients with cancer with severe pain, reported the Associated Press. The settlement comes a month after Insys founder John Kapoor and other former executives of the company were convicted of bribing doctors to prescribe the drug. As part of the agreement, the company will enter a 5-year deferred prosecution agreement with the Justice Department and its operating subsidiary will plead guilty to 5 counts of mail fraud.
Medicaid enrollees who would potentially be subject to Medicaid work requirements implemented by their state are more likely to face barriers to sustained employment compared with privately insured adults, according to a brief from the Urban Institute. Barriers include low education level, health problems, limited transportation and internet access, criminal history, and residence in high-unemployment or high-poverty neighborhoods. Less than 1 in 6 potentially affected Medicaid enrollees reported working at least 20 hours per week for nearly all weeks in the past year, compared with more than 3 in 5 privately insured adults.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More